

Tom Sawyer
Chief Financial Officer
– Cognitivity Neurosciences






BRINGING BRAIN HEALTH INTO THE 21ST CENTURY



Cognetivity
Neurosciences

Dr Thomas Sawyer



Our Vision



To establish the global
standard for brain health



Screening tools that have made an impact



Blood pressure

Cardiovascular disease



Cancer screens

Various cancers



Cholesterol

Heart attack and stroke



Weight and height

Diabetes and general health

Fast, cheap, easy to administer routine tests have transformed healthcare

But what about our brains?

No regular assessment for the most important organ in our bodies



Maintaining a healthy brain during life is the primary goal in pursuing health and longevity



Burden of neurological disorders and challenges for the preservation of brain health are increasing

Cognitive impairment is a symptom of a wide range of brain health issues, such as:

**Dementia,
55m patients¹**

**Depression,
300m patients¹**

**Anxiety,
40m patients¹**

**Brain injury,
75m patients¹**

**Other
neurological
disorders**

Early detection leads to far better patient outcomes and a dramatically reduced cost of care (dementia alone saves **\$7.9 trillion²**)

1. World Health Organisation 2020, global prevalence

2. Alzheimer's Association 2018

Tools for measuring cognitive impairment have flaws



LACK OF PRECISION



IMPRACTICALITY




**LANGUAGE
DEPENDENCE**



**EDUCATION
BIAS**



**A LEARNING
EFFECT**



How do you address a \$1 trillion
global health problem without
adequate instruments?



Introducing CognICA™

An intelligent SaaS solution






How CognICA™ works

Images are displayed for a fraction of a second.
Users tap to classify each in turn as **animal** or **non-animal**.



Using speed and accuracy as a digital biomarker allows an accurate and effective assessment of cognitive function.





Comparing different detection methodologies

CognICA has the attributes to become a standard, routine assessment

METHOD	FAST	LOW-COST	NON-INVASIVE	SENSITIVE	EARLY-STAGE DETECTION	DELIVERABLE REMOTELY	REIMBURSABLE
CognICA™	✓	✓	✓	✓	✓	✓	✓
Traditional pen-and-paper tests	✗	✓	✓	✗	✗	✗	✓
Computerized traditional tests	✗	✗	✓	✗	✗	✓	✓
Biomarker analysis (CSF sampling)	✗	✗	✗	✓	✗	✗	✓
Neuroimaging (MRI, CT)	✗	✗	✓	✓	✗	✗	✓



About us



Cambridge
University
Spin-out



Advanced
Technology



Market
Ready



Established
Partnerships

Specialist /
Remote
Assessment



Treatment
Monitoring



Screening Primary
Care



Depression /
PTSD



Population health
management



Healthcare System management



Corporate health /
anxiety




Different Use Cases in Industry

Ongoing studies in concussion, depression, PTSD, MS

The current pathway for brain health


Patients are not supported, and the system is inefficient



Patients are not reliably identified at an early stage – relies on subjective assessment and self reporting leading to **wrong people being sent to specialists**
If not identified, people drop out of the system

Transforming the pathway using CognICA


The ICA supports patients throughout the entire journey, allowing greater efficiency



Data are always available to clinicians throughout the process via EHR integration

The vision – universal availability

Cognetivity's technology available anywhere, anytime via SDK





The Vision – Brain Health Democratized

No-one should have to Suffer Alone

Cognetivity Neurosciences Ltd.

CSE:CGN
OTCQB:CGNSF

N America office:

Suite 1980, 1075 W. Georgia St.
Vancouver BC, V6E 3C9
Canada

European office:

3 Waterhouse Square
138 Holborn
London EC1N 2SW
UK

Middle East office:

Dubai Internet City, Block 16
Dubai, UAE

